Regeneron Pharma (REGN) PT Lowered to $1,150 at Morgan Stanley

Morgan Stanley analyst Matthew Harrison lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,150.00 (from $1,185.00) while maintaining a Overweight rating.

The analyst comments "In conjunction with 4Q EPS REGN announced that the company is initiating a dividend (~0.5% yield), which in our view from a timing perspective was ahead of expectations. This follows the path of other large cap US biotechs such as AMGN and GILD and should help broaden the potential shareholder base."

You May Also Be Interested In

• SpaceX (SPCX) gains nearly 6% as traders follow the money
• Seaport Global Securities Downgrades JetBlue Airways (JBLU) to Neutral
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings